New research data reflect patient satisfaction following faricimab treat-and-extend regimen

News
Article

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

A patient covers her eye to perform a Snellen chart test as the optometrist looks on. Image credit: ©megaflopp – stock.adobe.com

Study results showed that the best-corrected visual acuity was maintained 6 months after the patients were switched to the faricimab treat-and-extend regimen Image credit: ©megaflopp – stock.adobe.com

A Japanese study found that switching to faricimab (Vabysmo, Genentech) treatment using a treat-and-extend (TAE) regimen seems to maintain the best-corrected visual acuity (BCVA) and extend the injection interval in patients with neovascular age-related macular degeneration (nAMD), resulting in enhanced satisfaction 6 months after patients were switched.1 Taiichi Hikichi, MD, who is in private practice in Sapporo, Japan, reported his findings in the Japanese Journal of Ophthalmology.

Dr Hikichi conducted a retrospective observational study of 48 consecutive eyes of 48 patients with nAMD who were switched to faricimab and followed for 6 months while they were on a TAE regimen. At the 6-month time point, the patients completed the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ).

The results showed that the BCVA was maintained 6 months after the patients were switched to the faricimab TAE regimen. In addition, the mean central foveal thickness decreased significantly (p < 0.001) at 6 months compared to the time at which patients started on faricimab from 372 ± 20 μm to 272 ± 14 μm.

The treatment interval following the switch was 10.45 ± 0.44 weeks, which differed significantly (p = 0.002) from the treatment interval of 6.72 ± 0.34 weeks at the time of the switch.

Dr Hikichi also reported that the MacTSQ total score of 58.8 ± 1.7 in eyes with a BCVA of 20/40 and better 6 months after the switch was significantly (p < 0.001). higher compared to that in eyes with a BCVA worse than 20/40 (48.2 ± 1.5). The MacTSQ total score of 56.8 ± 1.8 in eyes in which a 4-week extension of the injection interval was achieved was significantly higher than the 49.5 ± 1.9 in eyes without (p < 0.001).

He concluded that switching to faricimab administered using a TAE regimen seems to maintain the BCVA and extend the injection interval in patients with nAMD, resulting in enhanced patient satisfaction.

Reference

1. Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652-6; https://doi.org/10.1007/s10384-023-01024-4
Recent Videos
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.